Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7647445 | 0.80 | ESR1 (0.46) | ESR1ESR2 | |
| SCHEMBL11131077 | 0.79 | ESR1 (0.54) | ESR1ESR2 | |
| SCHEMBL1119513 | 0.77 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL2478648 | 0.75 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL28740900 | 0.75 | ESR1 (0.30) | ESR1ESR2 | |
| SCHEMBL1031288 | 0.75 | DEGS1 (0.33) | ESR1ESR2 | |
| SCHEMBL1032464 | 0.75 | DEGS1 (0.33) | ESR1ESR2 | |
| SCHEMBL1031215 | 0.75 | DEGS1 (0.33) | ESR1ESR2 | |
| SCHEMBL5606447 | 0.74 | — | — | |
| SCHEMBL536997 | 0.72 | DPP4 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5075339-A | Antiinflammatory agents, antiallergens | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-24 | — | — | US | claimed |
| US-4948813-A | Benzylketone phospholipase A2 inhibitors | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-08-14 | — | — | US | claimed |
| CN-110265325-B | Substrate processing system and substrate cleaning method | 东京毅力科创株式会社 | 2023-05-23 | — | — | CN | disclosed |
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| EP-2990404-B1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL CO (JP) | 2020-05-27 | — | — | EP | disclosed |
| EP-3029030-B1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | SUMITOMO CHEMICAL CO (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-10077254-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-09-18 | — | — | US | disclosed |
| US-9867372-B2 | Tetrazolinone compound and use of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-16 | — | — | US | disclosed |
| CN-105636955-B | Tetrazolinone compound and use thereof | 住友化学株式会社 | 2018-01-12 | — | — | CN | disclosed |
| EP-3059233-B1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | SUMITOMO CHEMICAL CO (JP) | 2017-12-20 | — | — | EP | disclosed |
| CN-104271571-B | Tetrazolinone compound and use thereof | 住友化学株式会社 | 2017-07-07 | — | — | CN | disclosed |
| US-20160081339-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
| EP-2990404-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | Sumitomo Chemical Company Limited (JP) | 2016-03-02 | — | — | EP | disclosed |
| EP-2841429-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| CN-104271571-A | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL CO | 2015-01-07 | — | — | CN | disclosed |
| CN-104245689-A | Tetrazolinone compounds and its use as pesticides | SUMITOMO CHEMICAL CO | 2014-12-24 | — | — | CN | disclosed |
| WO-2013162072-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-31 | — | — | WO | disclosed |
| US-5075339-A | Antiinflammatory agents, antiallergens | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-24 | — | — | US | disclosed |
| US-4948813-A | Benzylketone phospholipase A2 inhibitors | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077254-B2 | Tetrazolinone compound and use thereof | MT-CO1, UQCRB, MT-CO2 | ESR1 2083/4885ESR2 2636/4885 |
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | CBR3, CYCS, CBR1 | ESR1 3552/4885ESR2 3939/4885 |
| US-20160081339-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | MT-CO1, SOD1, MT-CO2 | ESR1 2245/4885ESR2 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.